Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00XVL
|
|||
| Former ID |
DNCL003790
|
|||
| Drug Name |
ITI-214
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 1/2 | [1] | |
| Complete androgen insensitivity syndrome [ICD-11: LD2A.4; ICD-10: E34.5] | Phase 1 | [2] | ||
| Immune dysregulation [ICD-11: 4A01.2; ICD-10: D89.8] | Phase 1 | [2] | ||
| Schizophrenia [ICD-11: 6A20] | Phase 1 | [3] | ||
| Company |
Intra-Cellular; Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H26FN7O
|
|||
| Canonical SMILES |
CN1C(=O)C2=C(N(N=C2N3C1=NC4C3CCC4)CC5=CC=C(C=C5)C6=NC(=CC=C6)F)NC7=CC=CC=C7
|
|||
| InChI |
1S/C29H26FN7O/c1-35-28(38)25-26(31-20-7-3-2-4-8-20)36(34-27(25)37-23-11-5-10-22(23)33-29(35)37)17-18-13-15-19(16-14-18)21-9-6-12-24(30)32-21/h2-4,6-9,12-16,22-23,31H,5,10-11,17H2,1H3/t22-,23+/m1/s1
|
|||
| InChIKey |
BBIPVJCGIASXJB-PKTZIBPZSA-N
|
|||
| CAS Number |
CAS 1160521-50-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 1 (PDE1) | Target Info | Inhibitor | [2], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03257046) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036537) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.